|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2002-1-4
|
|
pubmed:abstractText |
Reactive oxidative species (ROS) produced by phagocytic cells have been ascribed a role in the localized suppression of lymphocyte function within malignant tumors. Histamine has been shown to inhibit ROS formation and possibly synergize with cytokines to permit activation of natural killer cells and T cells. This study was designed to determine whether the addition of histamine to a subcutaneous (SC) regimen of interleukin-2 (IL-2) would improve the survival of metastatic melanoma patients.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:AgarwalaSanjiv SSS,
pubmed-author:AllenA GAG,
pubmed-author:BeltRobertR,
pubmed-author:FeunLynnL,
pubmed-author:GehlsenKurt RKR,
pubmed-author:GlaspyJohnJ,
pubmed-author:GonzalezReneR,
pubmed-author:GutheilJohnJ,
pubmed-author:HellstrandKristofferK,
pubmed-author:HershEvanE,
pubmed-author:KirkwoodJohn MJM,
pubmed-author:MeyskensFrankF,
pubmed-author:MitchellMalcolmM,
pubmed-author:NarediPeterP,
pubmed-author:O'DaySteven JSJ,
pubmed-author:WhitmanEricE
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
125-33
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11773161-Adult,
pubmed-meshheading:11773161-Aged,
pubmed-meshheading:11773161-Aged, 80 and over,
pubmed-meshheading:11773161-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11773161-Consumer Product Safety,
pubmed-meshheading:11773161-Drug Synergism,
pubmed-meshheading:11773161-Female,
pubmed-meshheading:11773161-Histamine,
pubmed-meshheading:11773161-Humans,
pubmed-meshheading:11773161-Injections, Subcutaneous,
pubmed-meshheading:11773161-Interleukin-2,
pubmed-meshheading:11773161-Male,
pubmed-meshheading:11773161-Melanoma,
pubmed-meshheading:11773161-Middle Aged,
pubmed-meshheading:11773161-Neoplasm Metastasis,
pubmed-meshheading:11773161-Proportional Hazards Models,
pubmed-meshheading:11773161-Prospective Studies,
pubmed-meshheading:11773161-Skin Neoplasms,
pubmed-meshheading:11773161-Survival Rate,
pubmed-meshheading:11773161-United States
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma.
|
|
pubmed:affiliation |
Melanoma Center, University of Pittsburgh Cancer Institute, 200 Lothrop Street, Pittsburgh, PA 15213-2582, USA. agarwalass@msx.upmc.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase III
|
